In this two-centre, open-label, randomised, crossover trial, we showed that, in adults with type 1 diabetes and HbA1c below 7·5%, day-and-night hybrid closed-loop insulin delivery significantly improved overall glucose control while reducing hypoglycaemia progressively by 50–75% at lower glucose thresholds compared with usual insulin pump therapy. Here, INS is linked to Hypoglycemia.